The content on this site is intended for healthcare professionals only
Dr Guilherme Perini speaks to ecancer about results from the KEYFORM-008 trial evaluating the combination of favezelimab, a LAG-3 inhibitor, and pembrolizumab in patients with relapsed or refractory classic Hodgkin lymphoma whose disease had progressed on prior PD-1-directed therapy.
He reports that the combination significantly improved progression-free survival compared with chemotherapy, with a higher proportion of patients remaining progression-free at 12 months and a longer duration of response.
Dr Perini explains that although objective response rates were lower with favezelimab and pembrolizumab than with chemotherapy, overall disease control was similar between the treatment groups and responses were more durable with the immunotherapy combination.
Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma
Fixed-duration targeted treatment as effective as TKI Inhibitor therapy for CLL
Exploring genomic insights in acute lymphoblastic leukaemia treatment
New genomic map of adult B-ALL identifies CEBPalt subgroup and highlights blinatumomab benefits in key high-risk molecular types
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
